Day: November 6, 2025

First participant dosed in Phase 1 trial of BGE-102, oral CNS-penetrant NLRP3 inhibitor, with initial SAD data expected by year-end Continued advancement of oral and parenteral APJ agonist programs targeting 2026 IND submissions EMERYVILLE, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) — BioAge Labs, Inc. (“BioAge”, “the Company”), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today provided business updates and reported its third quarter 2025 financial results. “The third quarter of 2025 marked an important milestone as we advanced BGE-102 into clinical development with the dosing of our first participant in the Phase 1 trial,” said Kristen Fortney, PhD, CEO and co-founder of BioAge. “We’re on track to...

– GAAP LOSS PER COMMON SHARE FROM CONTINUING OPERATIONS OF $(0.13) –– DISTRIBUTABLE LOSS PER COMMON SHARE OF $(0.94) –– DISTRIBUTABLE LOSS PER COMMON SHARE BEFORE REALIZED LOSSES OF $(0.04) –       NEW YORK, Nov. 06, 2025 (GLOBE NEWSWIRE) — Ready Capital Corporation (“Ready Capital” or the “Company”) (NYSE: RC), a multi-strategy real estate finance company that originates, acquires, finances, and services lower-to-middle-market (“LMM”) investor and owner-occupied commercial real estate loans, today reported financial results for the quarter ended September 30, 2025. “Our primary focus continues to be restoring financial health,” said Thomas Capasse, Ready Capital’s Chairman and Chief Executive Officer. “Through our decisive exit strategies for our underperforming loan and real estate exposure...

Direct Premiums Written Grow 14% and Net Income Increases 56% to $10.9 Million Management to Host Conference Call Tomorrow at 8:30 a.m. Eastern Time KINGSTON, N.Y., Nov. 06, 2025 (GLOBE NEWSWIRE) — Kingstone Companies, Inc. (Nasdaq: KINS) (“Kingstone” or the “Company”), a Northeast regional property and casualty insurance holding company, today announced its financial results for the third quarter ended September 30, 2025. The Company has also provided an investor presentation that can be accessed through the News & Events/Presentations section of the Company website at www.kingstonecompanies.com.Key Financial and Operational Highlights              Quarters Ended Nine Months Ended  September 30, September 30,($ in thousands, except per share data)   2025     2024   Change   2025     2024   ChangeDirect premiums...

Quarter Sales of $203.8 million, up 62% from a year earlier, Quarter Net Income of $27.6 million, up 59% from a year earlier, Diluted EPS $1.20 for the Quarter, up 60% from a year earlier. WOOD DALE, Ill., Nov. 06, 2025 (GLOBE NEWSWIRE) — Power Solutions International, Inc. (the “Company” or “PSI”) (Nasdaq: PSIX), a leader in the design, engineering and manufacture of emission-certified engines and power systems, announced its record financial results for the third quarter 2025. Financial Highlights($ in millions, except per share amounts) Quarter Ended    September 30, 2025 September 30, 2024 ChangeNet Sales $203.8 $125.8 62%Gross Profit $48.7 $36.4 34%Net Income $27.6 $17.3 59%Diluted Earnings per Share $1.20 $0.75 $0.45Third Quarter 2025 Results PSI reported record net sales of $203.8 million and net income...

Selected HighlightsThird quarter Operating EBITDA* of negative $28.1 million (net loss of $80.8 million), including a non-cash inventory impairment of $20.4 million, compared to positive $50.5 million (net loss of $17.6 million) in the same quarter of 2024 Combined industry wide challenges stemming from the global economic and trade environment, higher fiber costs and pulp grade substitution intensified in the third quarter of 2025 Continued execution of our “One Goal One Hundred” program, targeting $100 million in cost savings and operational efficiency actions by the end of 2026 and taking additional steps aimed at improving liquidity through further cost reductions, lowering capital expenditures in 2026 and other working capital measuresNEW YORK, Nov. 06, 2025 (GLOBE NEWSWIRE) — Mercer International Inc. (Nasdaq:...

–First participants dosed in Phase 1 clinical trial of SL-325 in healthy volunteers – – Closed a private placement of up to $103 million in August 2025 to support advancement of SL-325 – – Appointments of Dan Baker, M.D., and Mona Ashiya, Ph.D. to the Board of Directors – AUSTIN, TX and DURHAM, NC, Nov. 06, 2025 (GLOBE NEWSWIRE) — Shattuck Labs, Inc. (Shattuck or the Company) (NASDAQ: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the treatment of patients with inflammatory and immune-mediated diseases, today reported financial results for the quarter ended September 30, 2025 and provided recent business highlights. “In the third quarter of 2025, SL-325 became the first DR3 blocking antibody to enter clinical development, and our Phase...

Dallas, Texas, Nov. 06, 2025 (GLOBE NEWSWIRE) — Valhi, Inc. (NYSE: VHI) reported a net loss attributable to Valhi stockholders of $22.2 million, or $.78 per share, in the third quarter of 2025 compared to net income of $57.5 million, or $2.01 per share, in the third quarter of 2024. For the first nine months of 2025, Valhi reported a net loss attributable to Valhi stockholders of $4.4 million, or $.15 per share, compared to net income of $85.2 million, or $2.99 per share, in the first nine months of 2024. Net income attributable to Valhi stockholders decreased in the third quarter and first nine months of 2025 as compared to the same periods in 2024 primarily due to lower operating results from the Chemicals Segment, a third quarter non-cash gain in 2024 related to the Chemicals Segment acquisition of the 50% joint venture interest...

Announces signing of $37.8m Supply Assurance Agreement with Merck Organizational changes streamline company and reduce operational expenses Cash runway extended through 2027 REDWOOD CITY, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) — Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for the efficient and scalable manufacturing of complex therapeutics, today announced financial results for the third quarter ended September 30, 2025. The company also provided a business update that includes signing a $37.8m Supply Assurance Agreement with Merck and organizational changes, together will allow the company to extend its cash runway through 2027. “We’ve had a very exciting and important few months that have set us up very well for the changes we are announcing today” said Stephen Dilly, MBBS, PhD, CEO and Chairman at...